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Abstract 
Coronavirus disease in 2019 (COVID-19) is a pandemic declared by the World Health Organization after its 
appearance in the Chinese city of Wuhan in late 2019. It has infected more than 30 million people worldwide 
and led to the death of nearly one million of them. Orexin-A (OXA), a neuropeptide produced by the lateral 
hypothalamic area and several peripheral tissues, regulates appetite, reproduction, and other physiological 
functions. There are many symptoms associated with infection with the coronavirus, such as a cytokine storm, 
narcolepsy, impaired senses of smell and taste, and loss of appetite, usually are associated with high or low 
levels of OXA in the infected people. Moreover, some chronic diseases such as cancer, diabetes, and obesity, 
generally referred to as risk factors for the disease, increase the severity of infection or even lead to death and 
they are associated with either an increase or a decrease in OXA levels. Moreover, some factors, such as a high 
testosterone level, facilitate the entry of a virus into the cells, which OXA controls. In this review, we described 
for the first time the potential impact of high or low levels of OXA on the severity of the symptoms of COVID-
19 or the death due to this disease. 
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Orexin-A (OXA) and Orexin-B (OXB) (also called 
hypocretin 1 and 2); are two neuropeptides 
discovered with their receptors in the lateral 
hypothalamic area (LHA) and have received 
widespread attention because of their diverse and 
vital functions. Both of them are derived from the 
precursor prepro-orexin (130 amino acids)1,2. There 
are two types of orexin receptor type 1 (OX1R), type 2 
(OX2R), G protein-coupled receptors, and their 
structure is highly conserved in mammals2. OX1R is 
selective for OXA, but OX2R has an almost equal 
affinity for both of them3,4. Despite many studies 
showing that orexins and their receptors just spread in 
the brain5,6; the subsequent studies, by using 
immunostaining, confirmed the presence of OXA also 
in various peripheral tissues, including myenteric 
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plexuses, ganglion cells of the sympathetic thoracic 
trunk, the islet cells of the pancreas, endocrine cells 
of the gastrointestinal tract, and both of 
syncytiotrophoblasts and decidual cells of the 
placenta. In addition, the prepro-orexin’s mRNA is 
expressed in the colon, kidney, pancreas, stomach, 
adrenal gland, placenta, ileum, and colorectal 
epithelial cells of human7. Orexins have many 
biological functions such as reproduction8, 9, 
appetite10, sleep/wake states11, development12, smell 
and taste13,14, and regulate the immune response15, in 
addition, his disorders are accompanied by many 
diseases such as cancer16, diabetes17, obesity18, and 
hypertension19. 
Coronavirus disease in 2019 (COVID-19), which 
first appeared in the city of Wuhan in central China’s 
Hubei province at the end of 2019 and spread rapidly 
in many countries of the world, caused by a novel 
coronavirus known as severe acute respiratory 
syndrome-coronavirus-2 (SARS-CoV-2)20. On the 
11th of March 2020, the World Health Organization 
(WHO) had declared COVID-19 a pandemic 
threatening the world21. Clinical symptoms of 
COVID-19 include fever, dry cough, shortness of 
breath, sore throat, sneezing, loss of smell, 
conjunctivitis, and rarely diarrhea22. WHO has 
reported similarities in clinical symptoms between 
the different strains of coronavirus, which include 
SARS-CoV-2, severe acute respiratory syndrome 
(SARS), and Middle East respiratory syndrome 
(MERS), which cause a respiratory syndrome with 
symptoms caused by influenza virus A (H1N1)23. 
Previous studies have indicated that the H1N1 causes 
narcolepsy, which results from the infection of the 
orexin–producing neurons in the hypothalamus24. 
From this standpoint and because of the possibility 
that either high or low levels of OXA and their 
receptors could be associated with the increase in the 
strength of symptoms in patients and the increased 
likelihood of death; we discussed in this review the 
correlation between high or low levels of OXA with 
increased severity of symptoms or a chance of death, 
this could be a new approach towards understanding 
the causes that result in the severity of the infection 
and finding appropriate solutions to address it. 
Orexin-A hypersecretion and COVID-19 
Hypersecretion of OXA is related to many factors that 
cause severe symptoms of COVID-19 or death, 
including high androgen levels and hypertension, 
besides some of the symptoms of COVID-19 like 
delirium (fig. 2). 
• Androgens  
OXA has a direct impact on the testis to stimulate it in 
order to increase its production of testosterone25,26. For 
example, in dogs, when the incubated fresh testis 
slices were treated with OXA, the synthesis of 
testosterone was stimulated in the normal and cryptic 
gonad, while this effect disappeared when OX1R 
antagonist SB-408124 was added27. The same result 
was obtained  in the South American camelid alpaca 
(Vicugna pacos) and male Wistar rats so that  OXA 
caused an increase in testosterone production by the 
testes or its fresh slices in a dose-dependent manner 
within a specific concentration range28-30. 
Furthermore, in primary rat Leydig cells, activation of 
OX1R by OXA had up-regulated testosterone 
production by extracellular signal-regulated protein 
kinase (ERK1/2) and mitogen-activated protein kinase 
(p38) signalling pathways31. On the other hand, OXA 
down-regulates aromatase mRNA, which transfers 
androgens to estradiol in the hypothalamus of the 
androgenized female rats32. However, 
radioimmunoassay in another study showed that OXA 
decreases the mean serum level of testosterone in male 
Wistar rats; and the treatment with OXA 
antagonists8,33 cancelled this effect. As for OXB we 
had a regulating effect on the secretion and production 
of testosterone by both myometrium and endometrial 
slices during early pregnancy and the oestrous cycle in 
the porcine uterus34. 
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Recently, several studies have been published that 
have correlated testosterone levels in males to the 
likelihood of infection COVID-19 or even the 
severity of symptoms35,36. A study showed that 
prostate cancer patients with high testosterone levels 
are more likely to be infected with COVID-19 than 
non-cancer patients37,38. In addition, a clear 
relationship between androgenic alopecia and male 
patients hospitalized with COVID-19 has been 
reported39,40. Moreover, European countries severely 
affected by COVID-19; have a high frequency of the 
adrenal-permissive allele  that encodes Hydroxy-
Delta-5-Steroid Dehydrogenase, 3 Beta- And Steroid 
Delta-Isomerase 1 (HSD3B1) that increases 
testosterone synthesis41. Not only high testosterone 
level could be a cause an increase in the risk of 
infection with COVID-19 or causing severe 
symptoms, but also the low levels of it; in other 
words, an increase in the mortality rate of the 
infected elderly have been observed, and this has 
been explained that those with lower levels of 
testosterone had a greater predisposition for the 
thrombosis, endothelial dysfunction, and a defective 
immune response42,43. Moreover, a high rate of 
hospitalized male COVID-19 patients with a high 
rate of hair loss was observed44.  
Many studies have indicated that regulation of 
transcription transmembrane protease serine 2 
(TMPRSS2) is mediated by androgen receptor45,46. 
Furthermore, TMPRSS2 receptor is largely accused, 
alongside  angiotensin-converting enzyme 2 (ACE2), 
of helping the coronavirus enter the target cells47, 48. 
Remarkably, it has been observed that the males 
exhibit COVID-19 severe symptoms compared to 
children who were more resistant to infection. This has 
been explained that the androgen receptors are 
responsible for regulating transcription of TMPRSS2, 
which is required for entry SARS-CoV-2 to the target 
cells49. An overbalance in the number of infected and 
deaths among males compared to females due to the 
greater expression of  ACE2, the critical receptor for 
virus entry into cells, has been reported50,51. In 
addition to the help provided by high testosterone 
levels in the entry of the coronavirus into target cells, 
it suppresses the immune system52,53 (Fig. 1). 
• Hypertension 
Using animal models of hypertension, several studies 
have shown that hypertension is associated with 
hyperactivity of the orexin neurons and the 
overexpression of orexin and its receptors54,55. To 
 
Figure 1. The potential mechanism by which OXA helps SARS-CoV-2 to enter the target cell. 
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some extent, patients with high blood pressure are 
more likely to develop severe symptoms of COVID-
19 and are more likely to die56,57. This may suggest 
that there could be a relationship between orexinergic 
system activity and severity of the symptoms of 
COVID-19 in hypertensive patients infected by the 
virus. 
• Delirium 
Delirium is one of the symptoms resulting from the 
effect of coronavirus on the central nervous system in 
COVID-19 infected patients, which is caused by the 
arrival of the virus to the nervous system and the 
occurrence of infections in it or hypoxia58. A positive 
correlation was found between death and severity of 
infection with COVID-19 on the one hand and access 
to delirium on the other hand, so that; it was clear 
that patients who had reached the stage of delirium 
were more likely to die59. Although the non-significant 
difference in plasma OXA levels between the delirium 
patient and non-patient had been reported60, the 
Suvorexant, an orexin receptor antagonist, is a 
recommended medication for treating delirium61,62. 
Orexin-A hyposecretion and COVID-19 
Some of the symptoms of COVID-19 include defects 
in the sense of smell and taste, loss of appetite, and 
narcolepsy besides risk factors that increase the 
severity of infection or even death, such as cytokine 
storm, ageing, cancer, diabetes, and obesity, are 
associated with a decrease in serum OXA levels (fig. 
2). 
• Cytokine storm 
The "cytokine storm", which is a hyperinflammatory 
 
Figure 2. The relationship between OXA and the symptoms and risk factors of COVID-19. This figure shows the accompaniment of some 
symptoms of COVID-19 and risk factors, causing severe symptoms and death, with hyper or hypo OXA secretion. 
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response, causes serious complications such as 
respiratory distress syndrome and thromboembolic 
diseases, one of the factors causing the increase in 
symptoms and the death rate in COVID-1963,64. A 
few studies have demonstrated the anti-inflammatory 
properties of OXA. In mice, peripheral 
administration of OXA reduced the levels of several 
proinflammatory cytokines and chemokines65. 
Additionally, OXA had relieved the inflammatory 
manifestations by inhibiting the NF-kB pathway in 
the murine model of experimental colitis66. 
Furthermore, pre-treatment of BV2 cells in vitro with 
OXA decreased the production of IL-6 and TNF-α67. 
Moreover, the endogenous orexin system alleviated 
the brain damage in the murine focal cerebral 
ischemia model, accompanied by a decline in IL-6 
and TNF-α68. Thus, from previous studies, low levels 
of OXA can increase the severity of inflammation. 
• Olfactory dysfunction  
Immunological detection of OXA and its receptors in 
different regions of the olfactory system, especially 
the olfactory bulb, indicated its potentially important 
role in the sense of smell in mice and rats69,70. It was 
hypothesized in a previous study that the impairment 
of smell in narcolepsy patients may be due to the loss 
of OXA in the central nervous system. This olfactory 
dysfunction has been remedied by administering 
OXA nasally71. It has become known that infection 
with COVID-19 may cause a defect in the sense of 
smell that can sometimes persist even after 
recovery72,73. 
• Loss of appetite 
Although orexins have been implicated in various 
physiological functions since its initial discovery, it 
has been known as an appetite-regulating peptide2. 
Outcomes indicated that OXA increases food intake 
by delaying the onset of a behaviourally normal 
satiety sequence10, and destruction of the lateral 
hypothalamus area, which is responsible for 
producing orexins, also led to underfeeding74. Loss 
of appetite is one of the symptoms of COVID-1975,76. 
• Taste dysfunction 
Inactivation of OXRs in the central nucleus of the 
amygdala, which is responsible for flavour-taste 
preference, by SB-334867 antagonist, caused a 
malfunction in the flavour-taste preference77, and 
blocked taste preference learning in the rats78. 
COVID-19 infection is significantly associated with 
impaired taste function and is considered an indication 
of infection79,80. 
• Ageing 
Although there is research indicating  a positive 
correlation between plasma OXA concentration and 
age in humans and that in both sexes, OXA levels in 
the plasma of people under 40 years old are lower than 
those of 60 years old or over81, 82. However, many of 
the behavioural, cognitive, and sleep disturbances seen 
in the elderly have been associated with decreased 
hypothalamic production of orexins83,84. In aged 
animal models, these animals had lower orexins-
producing neurons in the hypothalamus and other 
regions of the brain85, 86. Moreover, immunoreactivity 
has indicated a decrease in the expression of orexins in 
the hypothalamus in older humans compared with 
younger adults, which leads to sleep disturbances87. 
Also, significantly decreased OX1R expression in the 
orexinergic systems was reported in the elderly rats 
compared to the young88. This confirms the role of 
orexin in ageing; in the case of stimulation of orexin, 
neuronal activity by designer receptors exclusively 
activated by designer drugs alleviates the impairments 
associated with ageing, such as anxiety-like behaviour 
in young and middle-aged mice89. Furthermore, 
intranasal OXA was able to diminish the age-related 
cognitive dysfunction in the aged rats13. The elderly, 
especially those with chronic diseases, are at high risk 
of developing severe symptoms of COVID-19 or even 
death90,91. 
• Cancer 
Although there are studies that have indicated the 
negative role of OXA and OX1R in some types of 
cancers, such as the pancreas and BGC-823 gastric 
cancer cells, by increasing proliferation and viability 
of cells and inhibiting apoptosis92, 93, However, orexins 
have had an anti-cancer role in more than one cell line 
derived from prostate cancer, LNCaP and DU145, 
accompany with OX1R overexpression that plays a 
role as an apoptotic regulator94-96. Also, in colon 
cancer, orexins had an inhibitory role for cancer cells 
and induced apoptosis dramatically even in cells 
resistant to 5-fluorouracil97. Ultimately, orexins tend to 
drive different types of cancers to apoptosis and 
prevent their proliferation. Therefore they could be 
promising therapies16.  Studies have indicated that 
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cancer patients have a higher chance of dying with 
COVID-19, in addition to showing more severe 
symptoms and admission in the intensive care unit 
and mechanical ventilation98, 99. 
• Narcolepsy 
Studies have indicated that narcolepsy is associated 
with decreased orexin levels and receptors or a loss 
of its producing neurons100,101. The relationship 
between narcolepsy and COVID-19 has been 
mentioned102, 103. 
• Diabetes 
Type 2 diabetes mellitus is associated with decreased 
levels of OXA because of the inverse correlation 
between insulin resistance and plasma OXA 
levels104. Furthermore, in pregnant women with 
gestational diabetes mellitus, OXA levels are 
significantly lower than control17. This could be 
explained by a study that indicated that a decrease of 
OXA causes stress in the endoplasmic reticulum in 
the liver, which causes the failure of the hepatic 
insulin signaling105. People with diabetes have been 
reported to be more likely to have more severe 
symptoms of COVID-19, need for mechanical 
ventilation, and death compared to non-diabetic 
people106, 107. 
• Obesity 
In a study, plasma OXA levels and orexin receptor 
activity in adipose tissue negatively correlated with 
body mass index (BMI) in obese subjects108, 109. 
Orexin via spontaneous physical activity and energy 
expenditure induces obesity resistance110. Also, mice 
that loss orexin-containing neurons acquired obesity 
despite consuming less food111. Furthermore, 
injection of OXA into the brain led to weight loss 
and thus played a dampening role in the rise of 
obesity112. In addition, mice deprived of orexins 
through a knockout or treatment with an ataxin toxin 
postnatal caused the emergence of obesity in later 
stages113. Reports indicate that COVID-19 patients 
who are already obese have more severe symptoms 
of COVID-19 and are at a higher risk of death114, 115. 
Conclusion 
High levels of OXA increase the severity of COVID-
19 infections by raising testosterone levels, which 
contributes to facilitating the entry of larger numbers 
of the coronavirus into target cells. In addition, some 
chronic diseases that increase the severity of the 
infection and the likelihood of death, such as 
hypertension, are associated with a rise in the levels of 
OXA. Also, COVID-19 infection is associated in some 
cases with delirium, accompanied by high levels of 
OXA. On the other hand, some factors causing the 
possibility of death with COVID-19, such as cytokine 
storm, ageing, obesity, cancer, diabetes, and clinical 
symptoms of COVID-19 such as loss of smell, taste,  
and narcolepsy, are associated with a decrease in the 
levels of OXA. All this prompts us to pay attention to 
this neuropeptide to investigate its involvement in the 
pathogenesis of this disease. 
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